SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet reported strong quarterly earnings and robust cloud growth, alongside a significantly higher-than-anticipated capital expenditure forecast for 2026, signaling aggressive AI investments. The market is actively discussing these results as a potential market-saving event and a clear commitment to AI leadership, even amidst some debate on the scale of spending.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending following better-than-expected Q4 earnings and achieving profitability, alongside a substantial stock buyback, which has bulls anticipating a significant rally. However, community discussion is divided, as some investors question the muted price action and the company's Q1 guidance, while others express ongoing concerns about long-term monetization strategies and leadership in the competitive social media sector.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending ahead of its upcoming earnings report, as the community debates whether its strong AI momentum with Gemini and Waymo will drive a market rally or if a "sell the news" reaction will trigger a broader tech sector pullback following its significant run.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is surging amid heightened community discussion driven by Google's substantial capital expenditure, signaling strong demand for its AI infrastructure, and fresh speculation about a massive custom silicon deal with OpenAI, positioning it as a key beneficiary in the rapidly expanding AI sector.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is actively discussed after its strong financial report, with the community balancing optimism for its AI and automotive growth against concerns regarding guidance and persistent competitive pressures in the semiconductor market.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm is trending after its Q3 earnings report revealed beats on revenue and EPS driven by AI-adoption and a strong Q4 revenue forecast, yet the stock experienced an immediate dip, sparking community debate about its high valuation versus its robust long-term growth story and new 'Physical AI' division.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending following mixed earnings, where an EPS beat was overshadowed by slightly missed revenue and lowered guidance, causing a sharp decline in share price. The community is actively debating whether this presents an oversold buying opportunity or reflects ongoing concerns about growth and tariff impacts.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic Inc. is trending after a strong earnings report exceeded revenue expectations and included a new customer win in the healthcare sector, fueling community excitement about its robotics and AI-driven warehouse automation solutions. While many celebrate significant gains, some investors debate the sustainability of the surge given its high valuation and recent stock offering.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy (FLNC) is seeing intense discussion after reporting a significant revenue increase and record backlog, driven by surging demand from AI data centers and new global projects. Despite an earnings miss, the community is weighing the company's reaffirmed outlook and its position as a leader in energy storage against ongoing profitability concerns and high short interest.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after announcing the acquisition of two new strategic sites that more than double its digital and power capacity to 2.8 GW, significantly advancing its pivot into AI and high-performance computing. This transformative news is fueling community discussion about a potential short squeeze and a major re-valuation of the stock, with many expecting further decoupling from Bitcoin's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether VYNE...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE...

Penny Stocks To Watch Now - December 17th

Direxion Daily TSLA Bear 1X Shares, Canopy Growth, VYNE Therapeutics, Better Choice, Rezolve AI, Bitfarms, and iRobot are the seven Penny stocks to watch today, according to MarketBeat's stock...

VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE shareholders. Upon completion...

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +10.53% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BTIG and H.C. Wainwright downgraded Vyne Therapeutics following topline results from the company’s Phase 2b trial of repibresib gel in nonsegmental vitiligo, which failed to meet both primary and secondary endpoints.BTIG analyst Julien Harrison downgraded the stock to ‘Neutral’ from ‘Buy’ and said the company will analyze the full dataset to guide next steps. He also noted that Vyne intends to seek a development and commercialization partner for repibresib.&nbsp;Harrison added that an update is expected in the coming weeks on both repibresib and VYN202, which is currently under partial clinical hold by the U.S. Food and Drug Administration.H.C. Wainwright analyst Joseph Pantginis also downgraded the stock to ‘Neutral’ from ‘Buy’ and removed the firm’s $4.5 price target, calling the trial outcome “a surprise” that “puts the company in a precarious position.”&nbsp;He said the firm will remain on the sidelines pending further clarity on repibresib, additional VYN202 data, or potential new asset acquisitions.Vyne said that the Phase 2b trial was a randomized, double-blind, vehicle-controlled study conducted at 45 sites across North America, enrolling 177 participants. The trial evaluated the once-daily topical administration of repibresib gel at 1%, 2%, and 3% concentrations compared to vehicle.&nbsp;The primary endpoint, defined as the proportion of patients achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index (F-VASI50) at week 24, was not met. The trial also missed a key secondary endpoint (F-VASI75).However, the company stated that the highest dose group showed a nominally statistically significant treatment effect in percent change from baseline (CFB) in both F-VASI and T-VASI scores at week 24.&nbsp;Vyne stated that the outcome was likely affected by a high vehicle effect and a higher-than-expected dropout rate in the active arms. As a result, the company has discontinued treatment in the extension phase and will terminate the trial.The company&nbsp;reported approximately $39.6 million in cash, cash equivalents, and investments as of June 30.&nbsp;Treatment-emergent adverse events (TEAEs) were more frequent in the repibresib arms, with application site pain being the most common. Eight subjects in the treatment group discontinued due to AEs, compared to none in the vehicle group. Most TEAEs were mild and resolved during the study.CEO David Domzalski said the company was disappointed by the outcome but remains confident in the potential of its InhiBET BET inhibitor platform.On Stocktwits, retail sentiment for Vyne was ‘extremely bullish’ late Wednesday amid&nbsp;an 11,800% surge in 24-hour message volume.One user said they went long on Vyne at&nbsp;$0.4189, calling the selloff part of the biotech cycle. “Every setback is a setup for a comeback,” they wrote, adding that while the vitiligo trial missed, the underlying science still showed promise.&nbsp;They also pointed to the FDA's recent move&nbsp;regarding the company’s psoriasis program and noted that Vyne has sufficient cash to operate into late 2026.<stembedurl>https://stocktwits.com/BulldogTheDip/message/623071473</stembedurl>Another user highlighted Vyne’s $39 million cash position, suggesting the stock could attract activist investors like Tang Capital Management. “If they step in, we could see a bounce,” the user wrote.<stembedurl>https://stocktwits.com/MadHatterTrades74/message/623051900</stembedurl><a href="https://stocktwits.com/symbol/VYNE">Vyne’s stock</a> has declined 88.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pharma stock. (Photo credit: Getty Images)

Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound

The company plans to seek a development and commercialization partner for repibresib and expects to provide an update on both repibresib and VYN202, which are currently under partial FDA clinical hold, in the coming weeks. 

Equity

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

VYNE Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

Current Price	$0.5773
Prev Close	$0.574
Open	$0.574
Dividend Yield	0.00%
50-Day Moving Average	$0.5013
Beta	1.02
Avg. Volume	503,565.00
PE Ratio	-0.73

52-Week High	$2.94
52-Week Low	$0.2805
Market Capitalization	$19.11M
EPS (Annual)	-$0.9353
Price to Book	0.57
Revenue Per Employee	$38,538.46
Enterprise Value/EBITDA	N/A

VYNE
VYNE Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest VYNE News

VYNEVYNE Therapeutics Inc